Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00224562
Status:
UNKNOWN
Last Update Posted:
2005-10-26
First Post:
2005-09-14
Brief Title:
The RATIO Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
The RATIO Registry French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Status:
UNKNOWN
Status Verified Date:
2004-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists infliximab etanercept and adalimumab A total of 486 medical units in metropolitan France participate in the RATIO registry All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians on the basis of the standardized case report form the hospitalisation summary and the microbiological and radiological results Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study Incidence of these diseases will be calculated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| INSERM | None | None | None |